---
document_datetime: 2025-12-02 05:06:35
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/actelsar-hct.html
document_name: actelsar-hct.html
version: success
processing_time: 0.145694
conversion_datetime: 2025-12-28 11:08:26.049685
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Actelsar HCT

[RSS](/en/individual-human-medicine.xml/66327)

##### Authorised

This medicine is authorised for use in the European Union

telmisartan / hydrochlorothiazide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Actelsar HCT](#news-on)
- [More information on Actelsar HCT](#more-information-on-actelsar-hct-672)
- [More information on Actelsar HCT](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Actelsar HCT. It explains how the Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Actelsar HCT.

For practical information about using Actelsar HCT, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Actelsar HCT and what is it used for?

Actelsar HCT is a medicine that contains two active substances, telmisartan and hydrochlorothiazide. It is used in adults who have essential hypertension (high blood pressure) that is not adequately controlled by telmisartan alone. 'Essential' means that the hypertension has no obvious cause.

Actelsar HCT is a 'generic medicine'. This means that Actelsar HCT is similar to a 'reference medicine' already authorised in the EU called MicardisPlus.

## How is Actelsar HCT used?

Actelsar HCT is available as tablets (40 mg or 80 mg telmisartan and 12.5 mg hydrochlorothiazide; 80 mg telmisartan and 25 mg hydrochlorothiazide) to be taken by mouth once a day with liquid. The dose of Actelsar HCT to be used depends on the dose of telmisartan that the patient was taking before: patients who were receiving 40 mg telmisartan should take the 40/12.5-mg tablets, and patients who were receiving 80 mg telmisartan should take the 80/12.5-mg tablets. The 80/25-mg tablets are used in patients whose blood pressure is not controlled using the 80/12.5-mg tablets or who have been stabilised using the two active substances taken separately before switching to Actelsar HCT.

The medicine can only be obtained with a prescription.

## How does Actelsar HCT work?

Actelsar HCT contains two active substances, telmisartan and hydrochlorothiazide.

Telmisartan is an 'angiotensin-II-receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II. Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels). By blocking the receptors to which angiotensin II normally attaches, telmisartan stops the hormone having an effect, allowing the blood vessels to widen.

Hydrochlorothiazide is a diuretic, which is another type of treatment for hypertension. It works by increasing urine output, reducing the amount of fluid in the blood and reducing the blood pressure.

The combination of the two active substances has an additive effect, reducing the blood pressure more than either medicine alone. By lowering the blood pressure, the risks associated with high blood pressure, such as having a stroke, are reduced.

## How has Actelsar HCT been studied?

Because Actelsar HCT is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, MicardisPlus. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefits and risks of Actelsar HCT?

Because Actelsar HCT is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Actelsar HCT approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Actelsar HCT has been shown to have comparable quality and to be bioequivalent to MicardisPlus. Therefore, the CHMP's view was that, as for MicardisPlus, the benefit outweighs the identified risk. The Committee recommended that Actelsar HCT be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Actelsar HCT?

Safety information has been included in the summary of product characteristics and the package leaflet for Actelsar HCT, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about Actelsar HCT

The European Commission granted a marketing authorisation valid throughout the European Union for Actelsar HCT on 13 March 2013.

Actelsar HCT : EPAR - Summary for the public

Reference Number: EMA/40540/2013

English (EN) (68.46 KB - PDF)

**First published:** 26/03/2013

**Last updated:** 26/03/2013

[View](/en/documents/overview/actelsar-hct-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-731)

български (BG) (97.56 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

26/03/2013

[View](/bg/documents/overview/actelsar-hct-epar-summary-public_bg.pdf)

español (ES) (69.28 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

26/03/2013

[View](/es/documents/overview/actelsar-hct-epar-summary-public_es.pdf)

čeština (CS) (93.7 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

26/03/2013

[View](/cs/documents/overview/actelsar-hct-epar-summary-public_cs.pdf)

dansk (DA) (67.92 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

26/03/2013

[View](/da/documents/overview/actelsar-hct-epar-summary-public_da.pdf)

Deutsch (DE) (69.9 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

26/03/2013

[View](/de/documents/overview/actelsar-hct-epar-summary-public_de.pdf)

eesti keel (ET) (68.84 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

26/03/2013

[View](/et/documents/overview/actelsar-hct-epar-summary-public_et.pdf)

ελληνικά (EL) (99.83 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

26/03/2013

[View](/el/documents/overview/actelsar-hct-epar-summary-public_el.pdf)

français (FR) (69.51 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

26/03/2013

[View](/fr/documents/overview/actelsar-hct-epar-summary-public_fr.pdf)

italiano (IT) (68.1 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

26/03/2013

[View](/it/documents/overview/actelsar-hct-epar-summary-public_it.pdf)

latviešu valoda (LV) (91.42 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

26/03/2013

[View](/lv/documents/overview/actelsar-hct-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (91.64 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

26/03/2013

[View](/lt/documents/overview/actelsar-hct-epar-summary-public_lt.pdf)

magyar (HU) (88.55 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

26/03/2013

[View](/hu/documents/overview/actelsar-hct-epar-summary-public_hu.pdf)

Malti (MT) (94.77 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

26/03/2013

[View](/mt/documents/overview/actelsar-hct-epar-summary-public_mt.pdf)

Nederlands (NL) (70.37 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

26/03/2013

[View](/nl/documents/overview/actelsar-hct-epar-summary-public_nl.pdf)

polski (PL) (94.28 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

26/03/2013

[View](/pl/documents/overview/actelsar-hct-epar-summary-public_pl.pdf)

português (PT) (70.64 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

26/03/2013

[View](/pt/documents/overview/actelsar-hct-epar-summary-public_pt.pdf)

română (RO) (90.29 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

26/03/2013

[View](/ro/documents/overview/actelsar-hct-epar-summary-public_ro.pdf)

slovenčina (SK) (94.37 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

26/03/2013

[View](/sk/documents/overview/actelsar-hct-epar-summary-public_sk.pdf)

slovenščina (SL) (87.62 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

26/03/2013

[View](/sl/documents/overview/actelsar-hct-epar-summary-public_sl.pdf)

Suomi (FI) (68.65 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

26/03/2013

[View](/fi/documents/overview/actelsar-hct-epar-summary-public_fi.pdf)

svenska (SV) (67.44 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

26/03/2013

[View](/sv/documents/overview/actelsar-hct-epar-summary-public_sv.pdf)

## Product information

Actelsar HCT : EPAR - Product Information

English (EN) (1.12 MB - PDF)

**First published:** 26/03/2013

**Last updated:** 13/05/2025

[View](/en/documents/product-information/actelsar-hct-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-249)

български (BG) (1.34 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/bg/documents/product-information/actelsar-hct-epar-product-information_bg.pdf)

español (ES) (1.12 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/es/documents/product-information/actelsar-hct-epar-product-information_es.pdf)

čeština (CS) (1.44 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/cs/documents/product-information/actelsar-hct-epar-product-information_cs.pdf)

dansk (DA) (1.09 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/da/documents/product-information/actelsar-hct-epar-product-information_da.pdf)

Deutsch (DE) (1.2 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/de/documents/product-information/actelsar-hct-epar-product-information_de.pdf)

eesti keel (ET) (1.18 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/et/documents/product-information/actelsar-hct-epar-product-information_et.pdf)

ελληνικά (EL) (1.5 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/el/documents/product-information/actelsar-hct-epar-product-information_el.pdf)

français (FR) (1.21 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/fr/documents/product-information/actelsar-hct-epar-product-information_fr.pdf)

hrvatski (HR) (1.24 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/hr/documents/product-information/actelsar-hct-epar-product-information_hr.pdf)

íslenska (IS) (1.15 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/is/documents/product-information/actelsar-hct-epar-product-information_is.pdf)

italiano (IT) (1.26 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/it/documents/product-information/actelsar-hct-epar-product-information_it.pdf)

latviešu valoda (LV) (1.25 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/lv/documents/product-information/actelsar-hct-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.41 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/lt/documents/product-information/actelsar-hct-epar-product-information_lt.pdf)

magyar (HU) (1.32 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/hu/documents/product-information/actelsar-hct-epar-product-information_hu.pdf)

Malti (MT) (1.57 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/mt/documents/product-information/actelsar-hct-epar-product-information_mt.pdf)

Nederlands (NL) (1.15 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/nl/documents/product-information/actelsar-hct-epar-product-information_nl.pdf)

norsk (NO) (1.18 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/no/documents/product-information/actelsar-hct-epar-product-information_no.pdf)

polski (PL) (1.39 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/pl/documents/product-information/actelsar-hct-epar-product-information_pl.pdf)

português (PT) (1.21 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/pt/documents/product-information/actelsar-hct-epar-product-information_pt.pdf)

română (RO) (1.36 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/ro/documents/product-information/actelsar-hct-epar-product-information_ro.pdf)

slovenčina (SK) (1.4 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/sk/documents/product-information/actelsar-hct-epar-product-information_sk.pdf)

slovenščina (SL) (1.38 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/sl/documents/product-information/actelsar-hct-epar-product-information_sl.pdf)

Suomi (FI) (1.11 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/fi/documents/product-information/actelsar-hct-epar-product-information_fi.pdf)

svenska (SV) (1.11 MB - PDF)

**First published:**

26/03/2013

**Last updated:**

13/05/2025

[View](/sv/documents/product-information/actelsar-hct-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000248682 08/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Actelsar HCT : EPAR - All Authorised presentations

English (EN) (11.78 KB - PDF)

**First published:** 26/03/2013

**Last updated:** 23/07/2014

[View](/en/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-639)

български (BG) (46.28 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/bg/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_bg.pdf)

español (ES) (17.05 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/es/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_es.pdf)

čeština (CS) (47.31 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/cs/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (12.3 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/da/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (12.16 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/de/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (11.75 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/et/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (50.36 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/el/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_el.pdf)

français (FR) (12.38 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/fr/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (25.04 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/hr/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (12.33 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/is/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_is.pdf)

italiano (IT) (12.97 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/it/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (43.28 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/lv/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (46.52 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/lt/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (44.26 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/hu/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (41.75 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/mt/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (16.47 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/nl/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (12.6 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/no/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_no.pdf)

polski (PL) (28.38 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/pl/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_pl.pdf)

português (PT) (12.48 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/pt/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_pt.pdf)

română (RO) (41.79 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/ro/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (43.3 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/sk/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (47.05 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/sl/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (12.28 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/fi/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (13.05 KB - PDF)

**First published:**

26/03/2013

**Last updated:**

23/07/2014

[View](/sv/documents/all-authorised-presentations/actelsar-hct-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Actelsar HCT Active substance

- telmisartan
- hydrochlorothiazide

International non-proprietary name (INN) or common name

- telmisartan
- hydrochlorothiazide

Therapeutic area (MeSH) Essential Hypertension Anatomical therapeutic chemical (ATC) code C09DA07

### Pharmacotherapeutic group

- Agents acting on the renin-angiotensin system
- Angiotensin II antagonists and diuretics

### Therapeutic indication

Treatment of essential hypertension.

Actelsar HCT fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.

Actelsar HCT fixed-dose combination (80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.

Actelsar HCT fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Actelsar HCT 80 mg / 12.5 mg (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.

## Authorisation details

EMA product number EMEA/H/C/002676

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Actavis Group PTC ehf

Dalshraun 1

Opinion adopted 17/01/2013 Marketing authorisation issued 13/03/2013 Revision 19

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Actelsar HCT : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (153.27 KB - PDF)

**First published:** 12/02/2025

**Last updated:** 13/05/2025

[View](/en/documents/procedural-steps-after/actelsar-hct-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Actelsar HCT : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (136.6 KB - PDF)

**First published:** 23/07/2014

**Last updated:** 12/02/2025

[View](/en/documents/procedural-steps-after/actelsar-hct-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Actelsar HCT-H-C-2676-A31-03 : EPAR - Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recomm...

English (EN) (48.81 KB - PDF)

**First published:** 30/09/2014

**Last updated:** 30/09/2014

[View](/en/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_en.pdf)

[Other languages (22)](#file-language-dropdown-18)

български (BG) (87.49 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/bg/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_bg.pdf)

español (ES) (50.51 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/es/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_es.pdf)

čeština (CS) (82.81 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/cs/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_cs.pdf)

dansk (DA) (49.01 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/da/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_da.pdf)

Deutsch (DE) (53.54 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/de/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_de.pdf)

eesti keel (ET) (50.6 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/et/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_et.pdf)

ελληνικά (EL) (89.54 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/el/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_el.pdf)

français (FR) (51.91 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/fr/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_fr.pdf)

hrvatski (HR) (80.12 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/hr/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_hr.pdf)

italiano (IT) (51.13 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/it/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_it.pdf)

latviešu valoda (LV) (81.63 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/lv/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_lv.pdf)

lietuvių kalba (LT) (82.54 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/lt/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_lt.pdf)

magyar (HU) (68.7 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/hu/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_hu.pdf)

Malti (MT) (84.23 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/mt/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_mt.pdf)

Nederlands (NL) (49.82 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/nl/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_nl.pdf)

polski (PL) (83.62 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/pl/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_pl.pdf)

português (PT) (49.74 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/pt/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_pt.pdf)

română (RO) (88.19 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/ro/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_ro.pdf)

slovenčina (SK) (81.5 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/sk/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_sk.pdf)

slovenščina (SL) (79.79 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/sl/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_sl.pdf)

Suomi (FI) (49.15 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/fi/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_fi.pdf)

svenska (SV) (50.18 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/sv/documents/scientific-conclusion/actelsar-hct-h-c-2676-a31-03-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recomm_sv.pdf)

Actelsar HCT-H-C-2676-A31-0003 : EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/PRAC/294920/2014

English (EN) (301.42 KB - PDF)

**First published:** 30/09/2014

**Last updated:** 30/09/2014

[View](/en/documents/variation-report/actelsar-hct-h-c-2676-a31-0003-epar-assessment-report-article-31_en.pdf)

## Initial marketing authorisation documents

Actelsar HCT : EPAR - Public assessment report

Adopted

Reference Number: EMA/163479/2013

English (EN) (323.66 KB - PDF)

**First published:** 26/03/2013

**Last updated:** 26/03/2013

[View](/en/documents/assessment-report/actelsar-hct-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Actelsar HCT

Adopted

Reference Number: EMA/CHMP/774027/2012

English (EN) (57.58 KB - PDF)

**First published:** 18/01/2013

**Last updated:** 18/01/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-actelsar-hct_en.pdf)

#### News on Actelsar HCT

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-may-2013) 17/05/2013

#### More information on Actelsar HCT

- [Renin-angiotensin-system (RAS)-acting agents: Article-31 referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### More information on Actelsar HCT

- [Renin-angiotensin-system (RAS)-acting agents - referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 13/05/2025

## Share this page

[Back to top](#main-content)